Cardinal Health Inc CAH
We take great care to ensure that the data presented and summarized in this overview for CARDINAL HEALTH INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CAH
View all-
Black Rock Inc. New York, NY30.8MShares$4.51 Billion0.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA30.6MShares$4.47 Billion0.09% of portfolio
-
State Street Corp Boston, MA12.7MShares$1.85 Billion0.08% of portfolio
-
Geode Capital Management, LLC Boston, MA6.39MShares$935 Million0.08% of portfolio
-
Morgan Stanley New York, NY4.91MShares$718 Million0.05% of portfolio
-
Jpmorgan Chase & CO New York, NY4.18MShares$611 Million0.05% of portfolio
-
Bank Of America Corp Charlotte, NC3.48MShares$509 Million0.04% of portfolio
-
Norges Bank Oslo, Q83.48MShares$509 Million0.08% of portfolio
-
Invesco Ltd. Atlanta, GA3.04MShares$444 Million0.09% of portfolio
-
Northern Trust Corp Chicago, IL2.99MShares$438 Million0.07% of portfolio
Latest Institutional Activity in CAH
Top Purchases
Top Sells
About CAH
Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and offers medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers, as well as provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.
Insider Transactions at CAH
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Aug 12
2025
|
Michelle D. Greene Chief Information Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,362
+31.88%
|
-
|
Aug 12
2025
|
Stephen M Mason CEO, GMPD Segment |
BUY
Grant, award, or other acquisition
|
Direct |
54,537
+37.86%
|
-
|
Aug 12
2025
|
Jessica L Mayer Chief Legal/Compliance Officer |
BUY
Grant, award, or other acquisition
|
Direct |
49,994
+32.23%
|
-
|
Aug 12
2025
|
Mary C. Scherer Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,029
+20.58%
|
-
|
Aug 12
2025
|
Ola M Snow Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,813
+36.5%
|
-
|
Aug 12
2025
|
Deborah Weitzman CEO, PSS Segment |
BUY
Grant, award, or other acquisition
|
Direct |
39,100
+30.71%
|
-
|
Aug 12
2025
|
Aaron E Alt Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
67,448
+39.71%
|
-
|
Aug 12
2025
|
Jason M. Hollar Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
245,420
+35.95%
|
-
|
Jun 30
2025
|
Ola M Snow Chief Human Resources Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,623
-13.34%
|
$605,041
$167.18 P/Share
|
Jun 30
2025
|
Jason M. Hollar Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,821
-2.95%
|
$972,107
$167.18 P/Share
|
Jun 30
2025
|
Stephen M Mason CEO, GMPD Segment |
SELL
Payment of exercise price or tax liability
|
Direct |
5,694
-14.0%
|
$950,898
$167.18 P/Share
|
Jun 30
2025
|
Jessica L Mayer Chief Legal/Compliance Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,176
-8.59%
|
$864,392
$167.18 P/Share
|
Mar 15
2025
|
Robert W Musslewhite Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,049
+50.0%
|
-
|
Mar 15
2025
|
Sudhakar Ramakrishna Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,049
+50.0%
|
-
|
Feb 15
2025
|
Michelle D. Greene Chief Information Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
636
-3.31%
|
$80,136
$126.21 P/Share
|
Feb 15
2025
|
Aaron E Alt Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,919
-5.21%
|
$241,794
$126.21 P/Share
|
Dec 02
2024
|
Ola M Snow Chief Human Resources Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
355
-1.29%
|
$43,310
$122.24 P/Share
|
Dec 02
2024
|
Mary C. Scherer Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
90
-1.03%
|
$10,980
$122.24 P/Share
|
Dec 02
2024
|
Jessica L Mayer Chief Legal/Compliance Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
676
-1.11%
|
$82,472
$122.24 P/Share
|
Dec 02
2024
|
Deborah Weitzman CEO, PSS Segment |
SELL
Payment of exercise price or tax liability
|
Direct |
632
-1.27%
|
$77,104
$122.24 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 526K shares |
---|---|
Exercise of conversion of derivative security | 32.6K shares |
Payment of exercise price or tax liability | 49.7K shares |
---|---|
Open market or private sale | 185K shares |
Bona fide gift | 943 shares |